What Has Been The Evolution of the Alzheimer's Drugs Market in Recent Years?
The alzheimer's drugs market has seen considerable growth due to a variety of factors.
• Recent years have seen a substantial increase in the size of the Alzheimer's drugs market. It is projected to expand from a value of $9.33 billion in 2024 to $10.19 billion in 2025, indicating a compound annual growth rate (CAGR) of 9.1%. Factors like a surge in the number of Alzheimer’s disease incidences, increased research and development funding, enhanced disease mechanism comprehension, global health drives, and rising public awareness and education have significantly contributed to the historical period's growth.
What Are the Future Growth Projections for the Alzheimer's Drugs Market?
The Alzheimer's Drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of Alzheimer's drugs is predicted to experience substantial expansion in the upcoming years, with a value expected to reach $14.47 billion in 2029, at a compound annual growth rate (CAGR) of 9.2%.
The predicted growth in the forecast period is attributed to the precision in medicinal approaches, targeted disease alteration, the identification and approval of biomarkers, drug development centered around the patient, as well as non-pharmacological interventions. Key trends during this forecast period include a variety of therapeutic methods, advancements in digital health solutions and diagnostic technologies, the use of artificial intelligence (AI) for drug discovery, regenerative medicine, and the increase in collaborations and partnerships.
What Are The Core Factors Supporting Growth In The Alzheimers Drugs Market?
As Alzheimer's disease becomes more prevalent, it is anticipated that the Alzheimer's drugs market will grow in response. Alzheimer's disease is a neurologic disorder that causes brain atrophy and cell death, progressively worsening over time. Alzheimer's medication is utilized to counteract memory loss, cognitive and reasoning issues, and difficulties in executing daily activities. These drugs can improve life quality and assist in maintaining independence. In a report issued by the Alzheimer’s Association, a US-based nonprofit organization focused on Alzheimer's care, support, and research, in May 2024, it was discovered that the count of American seniors aged 65 and older with an Alzheimer's dementia diagnosis went up from 6.5 million in 2022 to an estimated 6.9 million in 2024. Hence, the escalating prevalence of Alzheimer's disease is fueling the expansion of the Alzheimer's drugs market.
What Are The Major Segments Within The Global Alzheimers Drugs Market?
The alzheimer's drugs market covered in this report is segmented –
1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Early To Moderate Stages, Moderate To Severe Stages
Subsegments:
1) By Donepezil: Oral Tablets, Oral Solution
2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches
3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules
4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules
Pre-Book The Alzheimers Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Alzheimers Drugs Market?
Leading businesses in the Alzheimer's drugs industry are pioneering groundbreaking products such as amyloid plaque-targeting therapies to enhance treatment methods and elevate patient results. This form of therapy concentrates on minimising or impeding the collection of amyloid-beta plaques in the brain, a characteristic of Alzheimer's disease. To exemplify, in June 2024, the United States-based pharmaceutical enterprise Eli Lilly and Company received the green light for Kisunla (donanemab-azbt) from the US-based public health guardians, the Food and Drug Administration (FDA). Kisunla (donanemab-azbt) holds the distinction of being the first and sole amyloid plaque-targeting treatment for early symptomatic Alzheimer's disease and functions by helping the body eliminate residual amyloid plaques from the brain, factors that contribute to cognitive deterioration in Alzheimer's patients. The drug is delivered as an intravenous infusion every four weeks with an initial dosage regimen of 700 mg for the initial three doses, escalating to 1400 mg thereafter. Kisunla is exclusively prescribed for adults with mild cognitive impairment (MCI) and mild dementia phases of Alzheimer's disease, yet only those with a verified amyloid pathology.
Who Are the Key Players In The Alzheimers Drugs Market?
Major companies operating in the alzheimer's drugs market include:
• AbbVie Inc.
• Daiichi Sankyo Company Limited
• F Hoffmann-La Roche AG
• Merck & Co Inc.
• Novartis AG
• Biogen Inc.
• AstraZeneca PLC
• Eisai Co Ltd.
• Eli Lilly and Company
• H Lundbeck A/S
• Pfizer Inc.
• Allergan PLC.
• Johnson & Johnson
• Lupin Pharmaceuticals Inc.
• Actiza Pharmaceutical Private Limited
• Neurotrope Inc.
• AC Immune SA
• Adamas Pharmaceuticals Inc
• Alzheon Inc.
• Anavex Life Sciences Corp
• Axsome Therapeutics Inc.
• Cassava Sciences Inc.
• Cognition Therapeutics Inc.
• Cortexyme Inc.
• Denali Therapeutics Inc
• EIP Pharma Inc.
• Enlivex Therapeutics Ltd.
• FORUM Pharmaceuticals Inc.
• Genentech Inc.
• Green Valley Pharmaceuticals LLC
• Intra-Cellular Therapies Inc.
• Karuna Therapeutics Inc.
• Neurim Pharmaceuticals Ltd
What Is The Most Dominant Region In The Alzheimers Drugs Market?
North Americawas the largest region in the Alzheimer's drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the Alzheimer’s drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
